1. Home
  2. DLTR vs GMAB Comparison

DLTR vs GMAB Comparison

Compare DLTR & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dollar Tree Inc.

DLTR

Dollar Tree Inc.

HOLD

Current Price

$112.55

Market Cap

24.4B

ML Signal

HOLD

GMAB

Genmab A/S ADS

HOLD

Current Price

$34.87

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLTR
GMAB
Founded
1986
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.4B
20.3B
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
DLTR
GMAB
Price
$112.55
$34.87
Analyst Decision
Hold
Strong Buy
Analyst Count
18
8
Target Price
$123.35
$39.56
AVG Volume (30 Days)
2.6M
2.1M
Earning Date
06-03-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
144.33
N/A
EPS
4.44
N/A
Revenue
$19,411,800,000.00
N/A
Revenue This Year
$8.48
$17.85
Revenue Next Year
$5.90
$16.04
P/E Ratio
$25.77
$1.90
Revenue Growth
10.43
N/A
52 Week Low
$84.71
$23.62
52 Week High
$142.40
$35.43

Technical Indicators

Market Signals
Indicator
DLTR
GMAB
Relative Strength Index (RSI) 34.04 66.47
Support Level $105.25 $32.38
Resistance Level $116.88 $35.43
Average True Range (ATR) 4.32 0.65
MACD -1.62 -0.01
Stochastic Oscillator 10.74 94.22

Price Performance

Historical Comparison
DLTR
GMAB

About DLTR Dollar Tree Inc.

Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2025, Dollar Tree generated over $19 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: